An FDA advisory panel voted Friday to allow compounding pharmacies to produce epitalon while narrowly recommending against the same permission for emideltide. Compounding pharmacies, for those unfamiliar with the term, are facilities licensed to prepare customized drug formulations outside the standard commercial supply chain. The pair of decisions closed out a two-day session in Washington that moved Health Secretary Robert F. Kennedy Jr. one step closer to his stated mission of making unapproved compounds more available to Americans.
What a compounding pharmacy can and cannot do
A compounding pharmacy fills a specific gap in the drug supply. It can prepare formulations a standard manufacturer does not offer, but it operates under rules that differ from those governing fully approved medicines. When an FDA advisory panel recommends that a specific compound be eligible for compounding, it signals that the substance has enough of a case to allow pharmacies to manufacture it for patients.
Epitalon cleared that bar Friday. Emideltide did not, and the vote against it was narrow, meaning the panel did not reach a clear consensus. A narrow rejection is not the same as a finding that the compound is unsafe; it means the panel, on balance, could not recommend moving forward.
Two days, six votes
Thursday's votes came first. That day, the same panel recommended allowing compounding pharmacies to manufacture four other peptides. Friday's votes on epitalon and emideltide brought the two-day tally to five favorable recommendations and one rejection.
Peptides are short-chain amino acids. They have grown popular in the United States, with social media influencers driving much of the demand. None of the peptides under review hold standard FDA approval. That unapproved status matters: standard commercial drug manufacturing requires FDA approval, and without it, compounding pharmacies represent one of the few legal routes for patients to obtain these compounds.
Kennedy's agenda and what comes next
Robert F. Kennedy Jr., who serves as health secretary, has made expanding access to unapproved compounds a central mission. The advisory panel's two-day session moved that goal forward on five fronts. Advisory panels provide recommendations; the FDA retains the authority to accept or reject them, and it has not yet acted on this week's guidance.
What Friday produced is a formal record: five peptides cleared for compounding consideration, one turned back. The narrow vote against emideltide is the detail that carries the most weight going forward.